Imatinib inhibition of fludarabine uptake in T-lymphocytes

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 735-739

  Woodahl, Erica L ^a,b   Wang, Joanne ^a,b   Heimfeld, Shelly ^b   Ren, Aaron G ^a   McCune, Jeannine S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Chronic myeloid leukemia; Fludarabine; Hematopoietic cell transplantation; Imatinib; Nucleoside transporters

Indexed keywords

ADENOSINE TRIPHOSPHATE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; FLUDARABINE; IMATINIB; NITROBENZYLTHIOINOSINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; PIPERAZINES; PYRIMIDINES; THIOINOSINE; VIDARABINE;

EID: 47549111536     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0629-y     Document Type: Article

References (22)

1. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum J Apperley F Cervantes J Cortes M Deininger A Gratwohl F Guilhot M Horowitz T Hughes H Kantarjian R Larson D Niederwieser R Silver R Hehlmann 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820
2. F Baron MB Maris BE Storer BM Sandmaier MJ Stuart PA McSweeney JP Radich MA Pulsipher ED Agura TR Chauncey DG Maloney JA Shizuru R Storb 2005 HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia Biol Blood Marrow Transplant 11 272 279
3. F Baron BM Sandmaier 2006 Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Leukemia 20 1690 1700
4. M Bornhauser N Kroger R Schwerdtfeger K Schafer-Eckart HG Sayer C Scheid M Stelljes J Kienast P Mundhenk S Fruehauf MG Kiehl H Wandt C Theuser G Ehninger AR Zander 2006 Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study Eur J Haematol 76 9 17
5. CE Cass JD Young SA Baldwin 1998 Recent advances in the molecular biology of nucleoside transporters of mammalian cells Biochem Cell Biol 76 761 770
6. HJ Deeg MB Maris BL Scott EH Warren 2006 Optimization of allogeneic transplant conditioning: not the time for dogma Leukemia 20 1701 1705
7. S Faderl M Talpaz Z Estrov S O'Brien R Kurzrock HM Kantarjian 1999 The biology of chronic myeloid leukemia N Engl J Med 341 164 172
8. V Gandhi W Plunkett 2002 Cellular and clinical pharmacology of fludarabine Clin Pharmacokinet 41 93 103
9. DA Griffith SM Jarvis 1996 Nucleoside and nucleobase transport systems of mammalian cells Biochim Biophys Acta 1286 153 181
10. M Huang Y Wang SB Cogut BS Mitchell LM Graves 2003 Inhibition of nucleoside transport by protein kinase inhibitors J Pharmacol Exp Ther 304 753 760
11. TF Kalhorn AG Ren JT Slattery JS McCune J Wang 2005 A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells J Chromatogr B Analyt Technol Biomed Life Sci 820 243 250
12. LP Koh WY Hwang CT Chuah YC Linn YT Goh CH Tan HJ Ng PH Tan 2003 Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis Bone Marrow Transplant 31 305 308
13. W Kong K Engel J Wang 2004 Mammalian nucleoside transporters Curr Drug Metab 5 63 84
14. A Korycka T Robak 2003 The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro Leuk Lymphoma 44 1549 1555
15. MB Maris D Niederwieser BM Sandmaier B Storer M Stuart D Maloney E Petersdorf P McSweeney M Pulsipher A Woolfrey T Chauncey E Agura S Heimfeld J Slattery U Hegenbart C Anasetti K Blume R Storb 2003 HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2021 2030
16. M Molina-Arcas B Bellosillo FJ Casado E Montserrat J Gil D Colomer M Pastor-Anglada 2003 Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia Blood 101 2328 2334
17. VG Oehler T Gooley DS Snyder L Johnston A Lin CC Cummings S Chu R Bhatia SJ Forman RS Negrin FR Appelbaum JP Radich 2007 The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood 109 1782 1789
18. B Peng M Hayes D Resta A Racine-Poon BJ Druker M Talpaz CL Sawyers M Rosamilia J Ford P Lloyd R Capdeville 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935 942
19. W Plunkett V Gandhi P Huang LE Robertson LY Yang V Gregoire E Estey MJ Keating 1993 Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies Semin Oncol 20 2 12
20. W Plunkett PP Saunders 1991 Metabolism and action of purine nucleoside analogs Pharmacol Ther 49 239 268
21. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340
22. JL Ward A Sherali ZP Mo CM Tse 2000 Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine J Biol Chem 275 8375 8381